Abstract B171: A novel tumor-microenvironment-based prognostic score in patients with primary operable colorectal cancer

Abstract

Abstract The tumor-associated inflammatory cell infiltrate and stroma hold independent prognostic value in patients with colorectal cancer. However, whether such measures hold complimentary prognostic value and how this may be applied alongside routine pathological staging remains unknown. The present study proposes a novel tumor microenvironment score, termed the Glasgow Microenvironment Score (GMS), comprising assessment of the inflammatory cell infiltrate (using Klintrup-Mäkinen grade (KM)) and tumor stroma percentage (TSP), with prognostic value independent of TNM stage. The GMS stratified patients into three prognostic groups: GMS=0 (strong KM), GMS=1 (weak KM/low TSP) and GMS=2 (weak KM/high TSP) with five-year cancer-specific survival of 89%, 75% and 51%, respectively (P<0.001). Furthermore, when combined with node status, venous invasion or mismatch repair status, GMS further stratified survival (92% to 37%, 93% to 27% and 100% to 37%, respectively). Indeed, the GMS is routinely available and may be readily validated in patients with primary operable colorectal cancer. Citation Format: James H. Park, Donald C. McMillan, Joanne Edwards, Paul G. Horgan, Campbell S.D. Roxburgh. A novel tumor-microenvironment-based prognostic score in patients with primary operable colorectal cancer. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(1 Suppl):Abstract nr B171.